Weekly Rundown: Key Catalysts for Small-Cap Stocks (December 1-5)

From recent disclosures to corporate shifts, we’ve highlighted the top small-cap catalysts to watch. Here’s your weekly preview (December 1-5).

--

Companies participating at Citi's 2025 Global Healthcare Conference, taking place from December 2–4, 2025, in Miami, FL, will include prominent names from across the healthcare sector:

• CABA • HCAT • DCGO • SKYE • SANA • CLOV

Companies participating at the Noble Capital Markets Emerging Growth Conference 2025, scheduled for December 2–3, 2025, will gather at the Florida Atlantic University Executive Education Complex in Boca Raton, Florida. The event will feature corporate presentations, fireside chats, and one-on-one meetings with qualified investors, offering a dynamic platform for middle-market public companies across various sectors to connect with the investment community.

• DCGO • VIVK • SLXN • INBS • SSP • BRLT • AYTU • NNBR • ICU • MYSZ • DIBS • CANF • OCGN • ATCH • TSQ • PERF • BCG • KBSX • ICG • CANF • SNAL

Companies participating at the 14th Annual Discovery One-on-One Conference by Benchmark Company, scheduled for December 4, 2025, will engage in one-on-one in-person meetings with investors in an intimate setting. This event is designed to foster direct, meaningful discussions between publicly traded micro- and small-cap companies and the investment community through focused, individualized meetings and small group sessions.

• ZENA • ROLR • DEFT • ODYS • ICG • SST • DAIO

Companies presenting at The 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, scheduled for December 1–4, 2025, in San Diego, California, will spotlight key advancements in Alzheimer’s disease diagnostics, research, and therapeutics. Established in 2008, CTAD is a major global platform where leading researchers, clinicians, and biopharmaceutical companies collaborate to accelerate treatment innovation and share clinical progress.

● ABOS > will present new findings including recruitment strategies for its Phase 2 ALTITUDE-AD study of sabirnetug, as well as data from a nonclinical Enhanced Brain Delivery (EBD™) study, which explores fusing transferrin receptor binders to sabirnetug to enhance blood-brain barrier transport.

● AVXL > will feature one late-breaking oral communication and two poster presentations focused on blarcamesine, highlighting its relevance in Alzheimer's therapeutic development.

● ANVS > will deliver two presentations covering recent progress in both its Alzheimer’s and Parkinson’s programs, emphasizing new biomarker data that support buntanetap's potential disease-modifying effects.

● INMB > will present data from the Phase 2 MINDFuL trial involving XPro1595, a selective soluble TNF neutralizer in early Alzheimer's disease with inflammation (ADi). A second presentation will cover validation of the Early Mild Alzheimer's Cognitive Composite (EMACC) through associations with blood-based Alzheimer’s biomarkers.

● LGVN > has been selected to present a poster titled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study.” The company believes these findings support the therapeutic promise of its cell-based therapy, laromestrocel.

● APM > will present two posters highlighting the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers for neurodegeneration, supporting future diagnostic approaches.

● CGTX > will present its proposed registrational Alzheimer’s disease study design, which has been accepted for presentation at the conference, reflecting progress in advancing its clinical strategy.

Companies participating at The 8th Annual Evercore Healthcare Conference will gather from December 2 to 4, 2025, at the Loews Coral Gables Hotel in Coral Gables, Florida. This prestigious event hosts over 200 leading healthcare companies, offering a vital forum for executives, innovators, and investors to engage in discussions around the latest healthcare trends, clinical developments, and market outlooks.

BFLY, GERN, CTMX, PRME, CMPS, IVVD RCKT, AGL, FHTX, CABA, HCAT, CRBU CNTB, ANL, IOBT, SABS, IBIO, IMUX ERAS, CCCC, AVIR, RANI, BMEA, JSPR ANTX, CATX, SKYE, OKUR, EQ, MGNX STTK, SANA, EDIT

Companies participating at The Piper Sandler 37th Annual Healthcare Conference will gather from December 2–4, 2025, at The Lotte New York Palace Hotel in New York City. The event features in-person presentations and fireside chats, with a live audio webcast available for remote participants. This conference serves as a key year-end forum for investors to hear directly from management teams across the healthcare landscape.

ATYR, STTK, CATX, TVRD, INO, SLDB ALLO, CLYM, OBIO, IOBT, ALXO, ABCL OPK, ESPR, CTKB, PACB, ALT, LXRX CMPS, STXS, GNLX, QNCX, WHWK, NSPR IPSC, TELA, BOLD, RBOT, ADGM, PALI IMMX, BDTX, NYXH, HYPR, STIM, SKYE IRD, ACRS, CTMX, FATE, GOSS, OTLK AKBA, BMEA, CRDF, EQ, CGTX, RCEL TKNO

Other companies with material events this week:

• AREB announced a new distribution partnership with Muller Distributing, marking its first entry into eastern Pennsylvania. On-premise launches are planned for early December 2025 to seed trial and drive velocity.

• PRPH will host a webinar on December 1, 2025, at 4:15 p.m. ET, highlighting its healthcare portfolio, patent milestones, receivables recovery efforts, and genomics business.

• BMR will participate at AWS re:Invent 2025 (Dec 1–5, Las Vegas), presenting GPU-accelerated video optimization solutions.

• KOPN will unveil a prototype of new wireless simulated binoculars at I/ITSEC 2025 in Orlando (Dec 1–4).

• VERI is hosting its virtual AI and Data Economy Investor Forum on Dec 1 at 12:00 p.m. ET, covering product strategy and market outlook.

• RBBN will attend the UBS TMT Conference (Dec 1–4).

• ELBM will present at the Northern Miner – International Metals Symposium in London (Nov 30–Dec 1), emphasizing Ontario’s battery materials potential.

• CRDL will host a webcast on Dec 1 to discuss ARCHER findings and implications for its inflammatory heart disease programs.

• ISPR will launch a new cannabis hardware ecosystem at MJBizCon 2025 (Dec 2–5, Las Vegas).

• MBRX CEO Walter Klemp will participate in the Virtual Investor Closing Bell Series on Dec 2 at 4:00 p.m. ET.

• ALIT CFO Jeremy Heaton will present at the UBS Global Technology & AI Conference in Scottsdale, AZ, on Dec 2 at 12:15 p.m. MST.

• UIS EVP & CFO Deb McCann will present at the BofA Leveraged Finance Conference on Dec 2 in Boca Raton, FL, at 2:10 p.m. ET.

• CANF will attend BioFIT 2025 (Dec 2–3, Strasbourg, France) focused on early-stage biotech/medtech collaborations.

• NWL CEO and CFO will join a fireside chat at the Morgan Stanley Global Consumer & Retail Conference on Dec 2 at 3:00 p.m. ET.

• EGY CEO George Maxwell will participate in a Water Tower Research investor fireside chat on Dec 2 at 11:00 a.m. ET.

• SST will attend the UBS Global Tech & AI Conference in Scottsdale, AZ, Dec 1–2.

• MERC will present at BofA Leveraged Finance (Dec 2–3, Boca Raton, FL) and UBS Industrials & Transportation (Dec 4, Palm Beach, FL).

• SND declared a special $0.05 dividend payable Dec 16 to shareholders of record as of Dec 2.

• XTIA will host an investor town hall via video conference on Dec 2 at 4:30 p.m. ET.

• TBLA will participate in the UBS Global Tech & AI Conference on Dec 2.

• SSP will present at BofA Leveraged Finance Conference on Dec 2 at 8:50 a.m. ET.

• RPAY CFO Rob Houser will host investor meetings at the UBS Tech & AI Conference in Scottsdale, AZ, on Dec 2.

• HOVR will participate in the MINERVA conference on Dec 2 in Ottawa.

• NVNO CEO Robert Berman will speak during a Virtual Investor CEO Connect on Dec 3 at 4:00 p.m. ET.

• AGEN will host its End-of-Year Stakeholder Webcast on Dec 3 at 4:00 p.m. ET, covering colorectal cancer progress and featuring a live Q&A.

• SLI CEO David Park will speak at Citi’s Basic Materials Conference in NYC on Dec 3 at 10:50 a.m. ET.

• KLXE will attend the Daniel Energy Partners Executive Series in NYC on Dec 3.

• RMNI will host its Investor Day 2025 in NYC on Dec 3, presenting growth strategies and its Agentic AI ERP solutions.

• CHAI will hold an investor conference call on Dec 4 at 4 p.m. ET to review strategy and long-term plans.

• SPWR will participate in the Jefferies Renewables & Clean Energy Conference in NYC on Dec 4.

• CADL will host a virtual R&D Event on Dec 5 (11:00 a.m.–1:45 p.m. ET), highlighting its viral immunotherapy pipeline.

• MNOV will present data from its Phase 2b/3 ALS trial at the ALS/MND Symposium (Dec 5–7, San Diego).

• LPCN will present two posters related to LPCN 2101 at the AES 2025 Annual Meeting (Dec 5–9, Atlanta). Poster topics include toxicokinetics and clinical pharmacokinetics of its novel anti-seizure therapy.

Looking ahead at companies presenting at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place from December 6–9, 2025, in Orlando, Florida, and will also be available online. This premier event in hematology will include hundreds of scientific sessions, thousands of abstract presentations, and extensive networking opportunities across academic, clinical, and industry stakeholders.

Companies expected to present include:

• CTOR/CTXR, BLRX, MRKR, HURA, SNTI, PRLD, CABA, INAB, CRIS, GERN, CLLS, AUTL, CASI, SLS, XCUR, IMMX, APVO, ALLO

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.